What is Helex?
Founded in 2021, Helex specializes in the development of genomic medicines specifically engineered to address chronic kidney diseases. The company distinguishes itself through the integration of two core technological pillars: a proprietary lipid nanoparticle delivery system designed for targeted renal administration and the Epic-Cure platform. This platform utilizes deep-learning algorithms to optimize CRISPR-based gene editing, ensuring high precision in guide RNA design. By focusing on complex conditions such as Autosomal Dominant Polycystic Kidney Disease, Helex is addressing a critical unmet need in the nephrology market, utilizing data-driven insights to mitigate off-target effects and enhance therapeutic safety profiles.
How much funding has Helex raised?
Helex has raised a total of $3.5M across 1 funding round:
Seed
$3.5M
Seed (2025): $3.5M with participation from Pi Ventures
Key Investors in Helex
Pi Ventures
Pi Ventures is a venture capital firm specializing in early-stage investments within the artificial intelligence, machine learning, and IoT sectors.
What's next for Helex?
With this major enterprise-level funding, Helex is well-positioned to accelerate its pipeline development and expand its operational footprint. The strategic roadmap likely involves scaling the Epic-Cure platform to validate additional therapeutic targets and advancing lead candidates toward preclinical milestones. As the company matures, the focus will shift toward establishing robust manufacturing capabilities and navigating the regulatory landscape for gene-editing interventions. This capital injection provides the necessary runway to solidify its market position, potentially attracting further partnerships with pharmaceutical incumbents seeking to bolster their portfolios with cutting-edge genomic assets.
See full Helex company page
